Company Overview - Gyre Therapeutics is a clinical-stage biotechnology company focused on developing anti-fibrotic therapeutics for chronic organ diseases [1][4] - The company is headquartered in San Diego, CA, and is advancing its lead product F351 (Hydronidone) for the treatment of NASH-associated fibrosis in the U.S. [4] Recent Developments - Gyre Therapeutics is expected to be added to the small-cap Russell 2000® and all-cap Russell 3000® Indexes effective after U.S. market close on June 28, 2024 [1][2] - The addition to the Russell Indexes is seen as a significant milestone for the company, enhancing its visibility as it advances its product F351 in both the PRC and the United States [2] Market Context - The Russell Indexes capture the 4,000 largest U.S. stocks as of April 30, 2024, ranked by total market capitalization [2] - Approximately $12.1 trillion in assets are benchmarked against the Russell U.S. Indexes, indicating the importance of these indexes for investment managers and institutional investors [3]
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes